gemcitabin

Phase 2Small molecule

GGerman Cancer Research Center

gemcitabin is one of 119 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Biliary Tract CancerActive, not recruiting

Non Muscle Invasive Bladder CancerRecruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Biliary Tract CancerPreclinical

Active, not recruiting

Non Muscle Invasive Bladder CancerPhase 2

Recruiting

Diffuse Large B-Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

109 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

38 2

Rituxan

Oncovin

33 4

Polivy

Roche

Phase 3

20 5

Gemzar

Johnson & Johnson

Phase 3

18 6

Adriamycin

Pfizer

Phase 3

18 7

Gazyva

Roche

Phase 3

18 8

Oncovin

Eli Lilly

Phase 3

18 9

Cytoxan

BBaxter Healthcare Corporation

Rayos

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT07480850

Q1 2029

Not yet recruiting

Biliary Tract Cancer

NCT07466238

Q4 2030

Phase 2Recruiting

Non Muscle Invasive Bladder Cancer

NCT07747740

Clinical

Trials by Indication[1]

Relapsed/Refractory1 trial

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Unknown status·—·Phase 2·NCT04405375·29 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·GGerman Cancer Research Center·Phase 1·NCT05494866·6 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting·—·Phase 2·NCT07480850·40 enrolled

Biliary Tract Cancer1 trial

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Not yet recruiting·PPeking University··NCT07466238·40 enrolled

Non-Small Cell Lung Cancer1 trial

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Completed·SSpanish Lung Cancer Group·Phase 3·NCT00446225·174 enrolled

1 more indication

Non Muscle Invasive Bladder Cancer1 trial

A Prospective, Randomized, Open-Label, Phase II Trial Comparing Sequential Intravesical Gemcitabine Plus Docetaxel With Sequential Intravesical Gemcitabine Plus Mitomycin C in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Recruiting·BBlokhin's Russian Cancer Research Center·Phase 2·NCT07747740·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for gemcitabin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — German Cancer Research Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGerman Cancer Research Center

gemcitabin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2029

Q4 2030

Trials by Indication[1]

Relapsed/Refractory1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Biliary Tract Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Non Muscle Invasive Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News